{
    "clinical_study": {
        "@rank": "111",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 13, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04342897"
        },
        "id_info": {
            "org_study_id": "17824",
            "secondary_id": "I7W-MC-UDAA",
            "nct_id": "NCT04342897"
        },
        "brief_title": "A Study of LY3127804 in Participants With COVID-19",
        "official_title": "A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients Who Are Hospitalized With Pneumonia and Presumed or Confirmed COVID-19",
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company",
                "agency_class": "Industry"
            }
        },
        "source": "Eli Lilly and Company",
        "oversight_info": {
            "has_dmc": "Yes",
            "is_fda_regulated_drug": "Yes",
            "is_fda_regulated_device": "No"
        },
        "brief_summary": {
            "textblock": "A randomized, double-blind, placebo-controlled, clinical trial of LY3127804 in participants\n      who are hospitalized with pneumonia and presumed or confirmed COVID-19. The study may last up\n      to 9 weeks and include daily visits up to day 28, and follow-up visits by phone."
        },
        "overall_status": "Not yet recruiting",
        "start_date": {
            "@type": "Anticipated",
            "#text": "April 18, 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "July 10, 2020"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "July 10, 2020"
        },
        "phase": "Phase 2",
        "study_type": "Interventional",
        "has_expanded_access": "No",
        "study_design_info": {
            "allocation": "Randomized",
            "intervention_model": "Parallel Assignment",
            "primary_purpose": "Treatment",
            "masking": "Double (Participant, Investigator)"
        },
        "primary_outcome": {
            "measure": "Number of Ventilator Free Days",
            "time_frame": "Day 1 to Day 28",
            "description": "Number of days on which a participant breathes without assistance"
        },
        "secondary_outcome": [
            {
                "measure": "Number of Participants Reporting Each Severity Rating on the National Institute of Allergy and Infectious Diseases (NIAID) Ordinal Assessment",
                "time_frame": "Day 1 to Day 28",
                "description": "The scale is an assessment of clinical status. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities"
            },
            {
                "measure": "Oxygen Saturation (SpO\u2082)",
                "time_frame": "Day 1 to Day 28",
                "description": "Oxygen Saturation"
            },
            {
                "measure": "Oxygen Flow Rate",
                "time_frame": "Day 1 to Day 28",
                "description": "Oxygen Flow Rate"
            },
            {
                "measure": "Mortality",
                "time_frame": "Post First Dose Up to Day 28",
                "description": "Mortality"
            },
            {
                "measure": "Length of Hospitalization",
                "time_frame": "Baseline up to at Least Week 6",
                "description": "Days of Hospitalization"
            },
            {
                "measure": "Number of Participants with any Serious Adverse Event (SAE)",
                "time_frame": "Day 1 up to Day 60",
                "description": "Number of Participants with any Serious Adverse Event (SAE)"
            },
            {
                "measure": "Number of Participants with any Treatment Emergent Adverse Event (TEAE)",
                "time_frame": "Day 1 up to Day 60",
                "description": "Number of Participants with any Treatment Emergent Adverse Event (TEAE)"
            }
        ],
        "number_of_arms": "2",
        "enrollment": {
            "@type": "Anticipated",
            "#text": "200"
        },
        "condition": [
            "COVID-19",
            "Pneumonia"
        ],
        "arm_group": [
            {
                "arm_group_label": "LY3127804",
                "arm_group_type": "Experimental",
                "description": "LY3127804 administered intravenously (IV), with standard of care treatment"
            },
            {
                "arm_group_label": "Placebo",
                "arm_group_type": "Placebo Comparator",
                "description": "Placebo administered IV, with standard of care treatment"
            }
        ],
        "intervention": [
            {
                "intervention_type": "Drug",
                "intervention_name": "LY3127804",
                "description": "Administered IV",
                "arm_group_label": "LY3127804"
            },
            {
                "intervention_type": "Drug",
                "intervention_name": "Placebo",
                "description": "Administered IV",
                "arm_group_label": "Placebo"
            }
        ],
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Are hospitalized with pneumonia, and presumed or confirmed COVID-19\n\n          -  Are able and willing to give signed informed consent (legally authorized\n             representative can provide informed consent if needed)\n\n        Exclusion Criteria:\n\n          -  Female participants must not be pregnant and/or lactating\n\n          -  Have Acute Respiratory Distress Syndrome (ARDS) or will require immediate intermittent\n             mandatory ventilation (IMV), or are ineligible for IMV\n\n          -  Have any concurrent serious medical condition (for example active malignancies on\n             chemotherapy, post organ transplant, dialysis) or concomitant medication that would\n             preclude participation in the study\n\n          -  Are moribund irrespective of the provision of treatments\n\n          -  Have a known history or show evidence of human immunodeficiency virus (HIV) and/or\n             hepatitis\n\n          -  Receiving full-dose anticoagulation therapy with warfarin or other anticoagulants\n\n          -  Have recently undergone major surgery or central venous access device placement\n\n          -  Have a significant bleeding disorder or vasculitis\n\n          -  Have experienced a thromboembolic event\n\n          -  Have symptomatic congestive heart failure, or symptomatic or poorly controlled cardiac\n             arrhythmia\n\n          -  Have a serious, nonhealing wound, peptic ulcer, or bone fracture\n\n          -  Have liver cirrhosis\n\n          -  Have a known sensitivity to monoclonal antibodies (mAbs) or other therapeutic proteins\n\n          -  Have a history of hypertensive crisis or hypertensive encephalopathy or current,\n             poorly controlled hypertension"
            },
            "gender": "All",
            "minimum_age": "18 Years",
            "maximum_age": "N/A",
            "healthy_volunteers": "No"
        },
        "overall_official": {
            "last_name": "Call 1-877-CTLILLY (1-877-265-4559 or 1-317-615-4559) Mon - Fri 9AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST)",
            "role": "Study Director",
            "affiliation": "Eli Lilly and Company"
        },
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or",
            "phone": "1-317-615-4559",
            "email": "ClinicalTrials.gov@lilly.com"
        },
        "verification_date": "April 2020",
        "study_first_submitted": "April 10, 2020",
        "study_first_submitted_qc": "April 10, 2020",
        "study_first_posted": {
            "@type": "Estimate",
            "#text": "April 13, 2020"
        },
        "last_update_submitted": "April 10, 2020",
        "last_update_submitted_qc": "April 10, 2020",
        "last_update_posted": {
            "@type": "Estimate",
            "#text": "April 13, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        },
        "keyword": [
            "Corona Virus Disease 19 (COVID-19)",
            "2019 Novel Coronavirus (2019 n-COV)",
            "Severe Acute Respiratory Syndrome (SARS)",
            "Pulmonary Disease",
            "SARS-CoV-2"
        ],
        "condition_browse": {
            "mesh_term": "Pneumonia"
        },
        "patient_data": {
            "sharing_ipd": "Yes",
            "ipd_description": "Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement",
            "ipd_info_type": [
                "Study Protocol",
                "Statistical Analysis Plan (SAP)",
                "Clinical Study Report (CSR)"
            ],
            "ipd_time_frame": "Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting",
            "ipd_access_criteria": "Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting",
            "ipd_url": "http://vivli.org/"
        }
    }
}